menu
    • menu

    Company profile for ArQule

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases. Our mission is to discover, develop and commercialize novel small molecule drugs that will dramatically extend and improve the lives of patients in areas of high unmet need. With four internally discovered drugs in multiple biomarker guided clinical trials and an enriched proprietar...
    ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases. Our mission is to discover, develop and commercialize novel small molecule drugs that will dramatically extend and improve the lives of patients in areas of high unmet need. With four internally discovered drugs in multiple biomarker guided clinical trials and an enriched proprietary kinase library from which to select additional drug candidates, ArQule is delivering on the potential of precision medicine by providing its patients with novel therapies for multiple hard to treat indications.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ArQuleUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    One Wall Street Burlington, MA 01803
    Telephone
    Telephone
    781-994-0300
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.arqule.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/arqule
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/ArQuleInc

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Merck Completes Acquisition of ArQule
    Merck Completes Acquisition of ArQule

    16 Jan 2020

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20200116005463/en

    BUSINESS WIRE
    16 Jan 2020
    Share Share
    After being repeatedly jilted, this biotech was swept off
    After being repeatedly jilted, this biotech was swept off

    18 Dec 2019

    // Jason Mast ENDPTS

    https://endpts.com/after-being-repeatedly-jilted-this-biotech-was-swept-off-its-feet-in-a-race-to-ash-inside-mercks-2-7b-arqule-buyout/

    Jason Mast ENDPTS
    18 Dec 2019
    Share Share
    Merck to Acquire ArQule, Advancing Leadership in Oncology
    Merck to Acquire ArQule, Advancing Leadership in Oncology

    10 Dec 2019

    // PRESS RELEASE

    https://www.mrknewsroom.com/news-release/oncology/merck-acquire-arqule-advancing-leadership-oncology

    PRESS RELEASE
    10 Dec 2019
    Share Share
    ArQule Announces Final Ph1 Clinical Data for Reversible BTK Inhibitor, ARQ 531
    ArQule Announces Final Ph1 Clinical Data for Reversible BTK Inhibitor, ARQ 531

    09 Dec 2019

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20191209005198/en/ArQule-Announces-Final-Phase-1-Clinical-Data/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==

    BUSINESSWIRE
    09 Dec 2019
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search